Gold prices fall as geopolitical tensions ease; U.S. CPI looms
John Turman, a director at USANA Health Sciences Inc . (NYSE:USNA), recently sold 500 shares of the company’s common stock. The transaction, which took place on March 11, was executed at an average price of $33.2954 per share, totaling approximately $16,647. Following this sale, Turman holds 4,026 shares of USANA Health Sciences. The company, based in Salt Lake City, operates in the medicinal chemicals and botanical products industry, boasting impressive gross profit margins of 81% and maintaining a healthy balance sheet with more cash than debt. According to InvestingPro analysis, USANA currently trades below its Fair Value, with a modest P/E ratio of 14.7x. Investors seeking detailed insights can access USANA’s comprehensive Pro Research Report, available exclusively on InvestingPro, along with analysis of 1,400+ other top stocks.
In other recent news, USANA Health Sciences reported mixed financial results and guidance that sparked investor concern. The company exceeded analyst expectations for the fourth quarter of 2024, with earnings per share (EPS) of $0.64, surpassing the forecasted $0.49, and revenue reaching $214 million against the anticipated $208.84 million. Despite this strong quarter, USANA’s guidance for fiscal year 2025 disappointed, with projected earnings per share ranging from $2.35 to $3.00, below the consensus estimate of $2.87. The company’s revenue outlook for FY2025, projected at $920-1000 million, only bracketed the consensus estimate of $934.5 million.
USANA’s acquisition of Hiya Health contributed to the fourth-quarter results, although its impact was minimal due to the late timing of the acquisition. For 2025, Hiya’s revenue is expected to grow by 29-42%, contributing $145-$160 million to USANA’s sales. Analysts from Tigress Financial Partners expressed interest in potential margin expansion through integration of Hiya’s operations. The company plans to launch over 20 new products in 2025 as part of its growth strategy, focusing on enhancing its direct selling model and increasing associate engagement.
USANA’s President and CEO, Jim Brown, noted positive momentum in the Americas and Europe but acknowledged challenges in key Asia Pacific markets. The company ended the year with $182 million in cash reserves, with plans to increase this by $50-$60 million in 2025. Despite the cautious consumer sentiment in some regions, USANA remains committed to its growth initiatives and strategic enhancements to its associate incentive programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.